Success Metrics

Active Trials
2(50%)

Phase Distribution

Ph phase_3
1
25%
Ph phase_1
1
25%
Ph phase_2
1
25%
Ph not_applicable
1
25%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Terminated(1)

Detailed Status

Recruiting2
Not yet recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
N/A1 (25.0%)

Trials by Status

not_yet_recruiting125%
recruiting250%
withdrawn125%

Recent Activity

2 active trials
Showing 4 of 4
not_yet_recruitingphase_3

A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease

NCT07740486
recruitingnot_applicable

Daratumumab for Late Antibody-Mediated Rejection

NCT07081126
recruitingphase_2

An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L

NCT06636552
withdrawnphase_1

A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

NCT05205252

Clinical Trials (4)

Showing 4 of 4 trials
NCT07740486Phase 3

A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease

Not Yet Recruiting
NCT07081126Not Applicable

Daratumumab for Late Antibody-Mediated Rejection

Recruiting
NCT06636552Phase 2

An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L

Recruiting
NCT05205252Phase 1

A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4